Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials

Levodopa-carbidopa intestinal gel (LCIG) provides continuous infusion and reduces “off” time in advanced Parkinson's disease (PD) patients with motor fluctuations despite optimized pharmacotherapy. Clinical experience with 2 LCIG dosing paradigms from phase 3 studies was examined. In an open-la...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Parkinsonism & related disorders Ročník 21; číslo 7; s. 742 - 748
Hlavní autori:	Lew, Mark F., Slevin, John T., Krüger, Rejko, Martínez Castrillo, Juan Carlos, Chatamra, Krai, Dubow, Jordan S., Robieson, Weining Z., Benesh, Janet A., Fung, Victor S.C.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Ltd 01.07.2015
Predmet:	Antiparkinson Agents - administration & dosage Antiparkinson Agents - metabolism Carbidopa - administration & dosage Carbidopa - metabolism Dosing Double-Blind Method Drug Combinations Female Gels Humans Internationality Intestinal Absorption - drug effects Intubation, Gastrointestinal - methods Jejunum - drug effects Jejunum - metabolism Levodopa - administration & dosage Levodopa - metabolism Levodopa-carbidopa intestinal gel Male Motor fluctuations Neurology Parkinson's disease PEG-J procedure Motor fluctuations Dosing PEG-J procedure Levodopa-carbidopa intestinal gel Parkinson's disease
ISSN:	1353-8020, 1873-5126, 1873-5126
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!